Publication: Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series
| dc.contributor.author | Josefin Ulriksdotter | en_US |
| dc.contributor.author | Cecilia Svedman | en_US |
| dc.contributor.author | Magnus Bruze | en_US |
| dc.contributor.author | Jenny Glimsjö | en_US |
| dc.contributor.author | Kajsa Källberg | en_US |
| dc.contributor.author | Thanisorn Sukakul | en_US |
| dc.contributor.author | Martin Mowitz | en_US |
| dc.contributor.other | Lunds Universitet | en_US |
| dc.contributor.other | Helsingborgs Lasarett | en_US |
| dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
| dc.contributor.other | Blekingesjukhuset | en_US |
| dc.date.accessioned | 2020-08-25T11:25:19Z | |
| dc.date.available | 2020-08-25T11:25:19Z | |
| dc.date.issued | 2020-01-01 | en_US |
| dc.description.abstract | © 2020 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. Background: Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. Objectives: To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. Methods: A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. Results: Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. Conclusions: Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary. | en_US |
| dc.identifier.citation | Contact Dermatitis. (2020) | en_US |
| dc.identifier.doi | 10.1111/cod.13649 | en_US |
| dc.identifier.issn | 16000536 | en_US |
| dc.identifier.issn | 01051873 | en_US |
| dc.identifier.other | 2-s2.0-85088638175 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/58318 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088638175&origin=inward | en_US |
| dc.subject | Medicine | en_US |
| dc.title | Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088638175&origin=inward | en_US |
